200
Participants
Start Date
May 8, 2017
Primary Completion Date
September 29, 2017
Study Completion Date
September 29, 2017
FluMist trivalent (2015-2016)
0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
FluMist Quadrivalent (2015-2016)
0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
FluMist Quadrivalent (2017-2018)
0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
Research Site, Binghamton
Research Site, Savannah
Research Site, Bardstown
Research Site, Dakota Dunes
Research Site, St Louis
Research Site, Omaha
Research Site, Norfolk
Research Site, Fort Worth
Research Site, San Angelo
Research Site, Tomball
Research Site, West Jordan
Research Site, Salt Lake City
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
MedImmune LLC
INDUSTRY